Hims & Hers Health 과거 수익 실적
과거 기준 확인 4/6
Hims & Hers Health은 연평균 28.3%의 비율로 수입이 증가해 온 반면, Healthcare 산업은 수입이 증가했으며, 연간 5.3%였습니다. 매출은 연평균 50%의 비율로 증가했습니다. Hims & Hers Health의 자기자본이익률은 23%이고 순이익률은 8.2%입니다.
주요 정보
28.3%
수익 성장률
55.2%
EPS 성장률
Healthcare 산업 성장 | 8.5% |
매출 성장률 | 50.0% |
자기자본 수익률 | 23.0% |
순이익 | 8.2% |
최근 수익 업데이트 | 30 Sep 2024 |
최근 과거 실적 업데이트
Recent updates
Hims & Hers Health: The Amazon Curse Is Being Overstated
Nov 15Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
Nov 05HIMS: GLP-1 Is Just The Beginning
Oct 17Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
Oct 03Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce
Oct 01Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now
Sep 24Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)
Aug 27Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
Aug 20Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Aug 11Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Aug 07Hims & Hers: The Thesis Goes Far Beyond GLP-1
Jul 18Hims & Hers: Buy The Dip To Catch The Next Rip
Jun 24Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge
Jun 19Hims & Hers: The Undervalued Gem Poised For Growth
Jun 18Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable
Jun 10Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead
May 21Hims & Hers Health: An Unforced Error
May 06Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
May 04Hims & Hers Health: Becoming A Market Leader Within The Growing Digital Health Industry
Apr 24Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation
Apr 05Hims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth Stock
Mar 21Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health
Mar 12Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%
Feb 28Hims & Hers: Turning The Profitability Corner And Returning 28%
Feb 25Hims & Hers Health: No Clear Moat Besides First Mover Advantage
Jan 23Hims & Hers Health: Unleashing Macro Momentum - Investing In Growth At A Higher Multiple
Jan 10Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)
Jan 07Hims & Hers Health Q3: The Cheapest Growth Stock Around
Dec 14Hims & Hers Health: What Would The Author Of 100 Baggers Say?
Nov 30Hims & Hers: The Most Undervalued Small Cap Stock I See
Nov 08Hims & Hers: A Promising Company With Resolvable Challenges
Nov 02Hims & Hers: Specialization Is The Secret To Great Growth
Oct 25Hims & Hers Health: Can't Get Much Better
Sep 25수익 및 비용 분석
수익 및 비용 분석
Hims & Hers Health 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Sep 24 | 1,242 | 101 | 893 | 68 |
30 Jun 24 | 1,067 | 18 | 802 | 60 |
31 Mar 24 | 959 | -2 | 743 | 53 |
31 Dec 23 | 872 | -24 | 693 | 48 |
30 Sep 23 | 793 | -36 | 639 | 43 |
30 Jun 23 | 711 | -47 | 581 | 39 |
31 Mar 23 | 616 | -59 | 514 | 34 |
31 Dec 22 | 527 | -66 | 446 | 29 |
30 Sep 22 | 444 | -86 | 381 | 26 |
30 Jun 22 | 374 | -83 | 324 | 35 |
31 Mar 22 | 321 | -73 | 281 | 28 |
31 Dec 21 | 272 | -108 | 289 | 22 |
30 Sep 21 | 229 | -82 | 250 | 17 |
30 Jun 21 | 196 | -72 | 217 | 0 |
31 Mar 21 | 171 | -63 | 186 | 0 |
31 Dec 20 | 149 | -18 | 113 | 11 |
30 Sep 20 | 132 | -25 | 117 | 0 |
30 Jun 20 | 112 | -38 | 114 | 0 |
31 Mar 20 | 95 | -58 | 117 | 0 |
31 Dec 19 | 83 | -72 | 119 | 0 |
31 Dec 18 | 27 | -75 | 84 | 0 |
양질의 수익: HIMS 은 높은 수익을 보유하고 있습니다.
이익 마진 증가: HIMS 는) 과거에 수익을 냈습니다.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: HIMS 지난 5년 동안 수익을 창출하여 매년 28.3% 수익을 올렸습니다.
성장 가속화: HIMS 지난해 흑자를 기록해 5년 평균과 비교하기 어려운 수익 성장률을 보이고 있습니다.
수익 대 산업: HIMS 작년에 수익을 올렸기 때문에 지난 해 수익 성장을 Healthcare 업계( 10.3% )와 비교하기가 어렵습니다.
자기자본 수익률
높은 ROE: HIMS 의 자본 수익률( 23% )은 높음으로 간주됩니다.